Finger acupoint electrical stimulation for thinking and memory problems after stroke
Tests gentle electrical stimulation of finger acupoints in adults with cognitive impairment after stroke.
Plain-language title generated from the registry record
Registry title: Evaluation of Clinical Efficacy and Mechanism of Hand Jing-Well Acupoint Transcutaneous Electrical Stimulation in Improving Post-Stroke Cognitive Impairment
Key facts
- Where
- Tianjin, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 35 and 80 years old?
Source: NCT07736885, who can take part
Where in China
- The First Teaching Hospital of Tianjin University of Traditional Chinese MedicineTianjin, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
- Trial code
- NCT07736885
- Record updated
- 30 July 2026
- Original description
This study evaluates a non-invasive electrical stimulation therapy applied to specific acupoints on the fingers (called Jing-Well points) to improve thinking and memory problems after stroke.Read full original descriptionShow less
Evaluation of Clinical Efficacy and Mechanism of Hand Jing-Well Acupoint Transcutaneous Electrical Stimulation in Improving Post-Stroke Cognitive Impairment
This study evaluates a non-invasive electrical stimulation therapy applied to specific acupoints on the fingers (called Jing-Well points) to improve thinking and memory problems after stroke.
Purpose: Many stroke survivors develop cognitive difficulties (problems with memory, attention, and decision-making). Current treatments are limited. This study tests whether gentle electrical stimulation to hand acupoints can improve these symptoms.
Who can participate: Adults aged [35-80] who have had an ischemic stroke and now have mild to moderate cognitive impairment.
What happens: Participants will be randomly assigned to receive either (1) active electrical stimulation to hand Jing-Well points, (2) sham (fake) stimulation. Treatment will last 4 weeks, 6 sessions per week, each 30 minutes, with a stimulation frequency of 10 Hz and intensity adjusted to each participant's tolerance. Cognitive tests and brain imaging will be done before and after treatment.
Potential benefits: Participants may experience improved cognitive function. The study will also help researchers understand how this therapy works in the brain.
Risks: The electrical stimulation may cause mild tingling or skin irritation at the electrode sites. Brain imaging is non-invasive and safe. All procedures will be performed by trained professionals.
Inclusion: Aged 35-80 years; Stroke duration within 2 weeks to 6 months post-onset; Cognitive impairment confirmed by neuropsychological assessment: Montreal Cognitive Assessment (MoCA) score < 26; Clinical evaluation excludes delirium, major depressive disorder, schizophrenia, or other primary psychiatric/behavioral disorders as the principal cause of current cognitive impairment. No history of other known neurological diseases that may cause cognitive impairment (e.g., multiple sclerosis, encephalitis, Parkinson's disease, post-traumatic dementia, normal pressure hydrocephalus, etc.); No severe aphasia; able to cooperate with scale assessments and complete the treatment protocol required by this study; Voluntary participation in this study; the participant or their legally authorized representative has signed the informed consent form.
Exclusion: Concurrent use of other medications affecting cognitive function; Implanted devices (cardiac pacemaker/defibrillator, deep brain stimulator, etc.); History of epilepsy or epileptic seizures; Allergy to the study intervention device or history of serious adverse reactions; Severe arrhythmia, malignant hypertension, or severe dysfunction of vital organs (heart, liver, kidney, etc.); Individuals unable to participate in treatment due to severe hearing or visual impairment, or bilateral limb paralysis; Unstable vital signs or life-threatening comorbidities; Pregnant or lactating women.